Avastin with chemotherapy didn't increase heart risk, Roche says

12/17/2007 | Bloomberg1

The combination of tumor drug Avastin with anthracycline-based chemotherapy did not heighten the risk of heart problems in breast cancer patients who underwent surgery, Roche Holding said Saturday. The company intends to finish two late-stage studies on the drug before seeking approval for expanding its use to different types of tumors and different stages of breast cancer.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ